Merck & Co Inc
NYSE:MRK
Merck & Co Inc
Other Long-Term Assets
Merck & Co Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$13.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
20%
|
CAGR 10-Years
10%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$20.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$7.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
4%
|
CAGR 10-Years
17%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$18.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Other Long-Term Assets
$790m
|
CAGR 3-Years
55%
|
CAGR 5-Years
34%
|
CAGR 10-Years
23%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$13.7B
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
7%
|
|
Merck & Co Inc
Glance View
Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.
See Also
What is Merck & Co Inc's Other Long-Term Assets?
Other Long-Term Assets
13.3B
USD
Based on the financial report for Dec 31, 2024, Merck & Co Inc's Other Long-Term Assets amounts to 13.3B USD.
What is Merck & Co Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
10%
Over the last year, the Other Long-Term Assets growth was 23%. The average annual Other Long-Term Assets growth rates for Merck & Co Inc have been 6% over the past three years , 20% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet